Non-surgical bidirectional Brain-Computer Interface powered by Nanoparticles
Subsense create first non-surgical, minimally invasive BCI platform to unite the human brain, technology, and AI — to transf
rm the treatment of neurological disorders
Subsense is a Bioplatform
Combination of nanoparticles inside the brain and wearable headset
provide a scalable solution for multiple applications
Biocompatible nanoparticle
Act as antennas to read + write
neural signals
Wearable hardware
Wireless connection & control
of nanoparticles
Bioplatform
Combination of nanoparticles inside the
brain and wearable headset provide a
scalable solution for multiple applications
Biocompatible nanoparticle
Act as antennas to read + write neural signals
Wearable hardware
Wireless connection & control of nanoparticles
We start with tightly cntrolled clinical and research settings, building safety, efficacy, and trust step by step
We start with tightly
cntrolled clinical and
research settings, building
safety, efficacy, and trust
step by step
HORIZON 1:
MEDICAL IMPACT
Our first product will provide accessible and safe neuro modulation and neural readings solutions for neurological diseases
Parkinson’s disease
6,000,000+
Parkinson’s patients don’t have an optimal treatment
Epilepsy
20,000,000+
Drug-resistant epileptic patients still
need a solution
Other neurological disorders
1 in 3 people
are affected by neurological conditions
SUBSENSE IMPACT
3,000,000,000+
Potential patients can be helped
Medicine is the foundation.
The horizon is much broader
HORIZON 2:
Beyond treatment
Once safety, precision, and scalability are proven in medicine, the same platform opens the door to entirely new human–technology interfaces
New forms of communication and perception
Human–AI interaction at the neural level
Cognitive extension and accelerated learning
Recognized by leading media
Recent significant events
Subsense raised $27M in Seed round+
Subsense, the maker of brain-computer interfaces (BCI) to treat neurodegenerative diseases, raised $10 million in additional seed funding, CEO Tetiana Aleksandrova tells Axios Pro exclusively.
Opened Lab in Palo Alto+
The future of brain-computer interfaces is not built in isolation. It takes conversation, collaboration, and a community that is ready to challenge assumptions.
Last week, we opened the doors to our new lab in Palo Alto, and it was inspiring to celebrate alongside so many who are shaping the field of BCI and neurotechnology. Guests joined for interactive demos, a panel of leading experts, and an evening of ideas that reminded us what is possible when disciplines come together.Opened Lab in Palo Alto
Early FDA Engagement Underway
Subsense has initiated early engagement with the FDA and presented its regulatory approach.
